# Tolerance Study of the Dietary Supplement Lipidrive (ECPH1-03)

> **NCT03052062** · PHASE1,PHASE2 · COMPLETED · sponsor: **Valbiotis** · enrollment: 20 (actual)

## Conditions studied

- Obese

## Interventions

- **DIETARY_SUPPLEMENT:** Lipidrive

## Key facts

- **NCT ID:** NCT03052062
- **Lead sponsor:** Valbiotis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-02
- **Primary completion:** 2018-07-03
- **Final completion:** 2018-07-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-07-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03052062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03052062, "Tolerance Study of the Dietary Supplement Lipidrive (ECPH1-03)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03052062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*